ZBIO Q2 2024 Earnings — Zenas BioPharma, Inc. Revenue & Financial Results | Market Cap Arena

ZBIOZenas BioPharma, Inc.

$1B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$34M

Operating Income

-$40M

Net Income

-$38M

EPS (Diluted)

$-0.99

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$200M

Total Liabilities

$39M

Stockholders' Equity

$161M

Cash & Equivalents

$184M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$34M	$0	—
Operating Income	-$40M	-$29M	-37.4%
Net Income	-$38M	-$29M	-30.7%